Chemoprotective effects of recombinant human IL-1a in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy
Futami, H.; Jansen, R.; Macphee, M.J.
Journal of Immunology 145: 21-30
1990
ISSN/ISBN: 0022-1767 Accession: 017814571
PDF emailed within 1 workday: $29.90
Related References
Futami, H.; Jansen, R.; MacPhee, M.J.; Keller, J.; McCormick, K.; Longo, D.L.; Oppenheim, J.J.; Ruscetti, F.W.; Wiltrout, R.H. 1990: Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy Journal of Immunology 145(12): 4121-4130Shim, J.Y.; Han, Y.; Ahn, J.Y.; Yun, Y.S.; Song, J.Y. 2007: Chemoprotective and adjuvant effects of immunomodulator ginsan in cyclophosphamide-treated normal and tumor bearing mice International Journal of Immunopathology and Pharmacology 20(3): 487-497
Lynch, D.H.; Rubin, A.S.; Miller, R.E.; Williams, D.E. 1993: Protective effects of recombinant human interleukin-1α in doxorubicin-treated normal and tumor-bearing mice Cancer Research (Baltimore) 53(7): 1565-1570
Lynch, D.H.; Rubin, A.S.; Miller, R.E.; Williams, D.E. 1993: Protective effects of recombinant human interleukin-1 alpha in doxorubicin-treated normal and tumor-bearing mice Cancer Research 53(7): 1565-1570
Futami, H.; Jansen, R.; Irino, S.; Keller, J.; Longo, D.L.; Oppenheim, J.J.; Ruscetti, F.W.; Wiltrout, R.H. 1990: Chemoprotective effects of rhil 1 alpha in normal and tumor bearing mice Proceedings of the American Association for Cancer Research Annual Meeting 31: 294
Aicher, K.P.; Dupon, J.W.; White, D.L.; Aukerman, S.L.; Moseley, M.E.; Juster, R.; Rosenau, W.; Winkelhake, J.L.; Brasch, R.C. 1990: Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha Cancer Research 50(22): 7376-7381
Aicher, K.P.; Dupon, J.W.; White, D.L.; Aukerman, S.L.; Moseley, M.E.; Juster, R.; Rosenau, W.; Winkelhake, J.L.; Brasch, R.C. 1990: Contract-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor α Cancer Research (Baltimore) 50(22): 7376-7381
Yang, T.; Shi, W.; Wumaierniyazi, Z.; Shan, L.; Miao, W.; Wu, G.; Zhou, B.; Yusup, A.; Upur, H.; Aikemu, A. 2017: Enhanced antitumor efficacy and reduced toxicity of Abnormal Savda Munziq on tumor bearing mice treated with chemotherapy Oncotarget 8(54): 92682-92698
Lin, G.; Yu, X.; Wang, J.; Qu, S.; Sui, D. 2013: Beneficial effects of 20(S)-protopanaxadiol on antitumor activity and toxicity of cyclophosphamide in tumor-bearing mice Experimental and Therapeutic Medicine 5(2): 443-447
Shen R.N.; Wu B.; Wang W.X.; Lu L.; Broxmeyer H.E. 1992: Interleukin 1 alpha accelerates recovery of neutrophils and immune function in mice treated with sublethal dosages of cyclophosphamide and reduces tumor growth and lung metastases in cyclophosphamide treated tumor bearing mice Experimental Hematology (Charlottesville) 20(6): 776
Hosokawa, M.; Kobayashi, H. 1988: Enhanced therapeutic effects of interleukin 2 when combined with cyclophosphamide on 3LL tumor in mice International Journal of Immunopharmacology 10(Supp-S1): 130-0
Bhanumathy, P.; Kumar, S.; Vasudevan, D.M. 1986: Role of 2'-mercaptopropionylglycine (MPG) against toxicity of cyclophosphamide in normal and tumour-bearing mice Indian Journal of Experimental Biology 24(12): 767-770
Bhattacharjee, A.; Basu, A.; Biswas, J.; Sen, T.; Bhattacharya, S. 2017: Chemoprotective and chemosensitizing properties of selenium nanoparticle (Nano-Se) during adjuvant therapy with cyclophosphamide in tumor-bearing mice Molecular and Cellular Biochemistry 424(1-2): 13-33
Krosnick, J.A.; Mcintosh, J.K.; Mule, J.J.; Rosenberg, S.A. 1989: Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor α in normal and tumor-bearing mice Cancer Immunology and ImmunoTherapy 30(3): 133-138
Welte, K.; Bonilla, M.A.; Gillio, A.P.; Boone, T.C.; Potter, G.K.; Gabrilove, J.L.; Moore, M.A.; O'Reilly, R.J.; Souza, L.M. 1987: Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates Journal of Experimental Medicine 165(4): 941-948
Krosnick, J.A.; McIntosh, J.K.; Mulé, J.J.; Rosenberg, S.A. 1989: Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor alpha in normal and tumor-bearing mice Cancer Immunology Immunotherapy: Cii 30(3): 133-138
Amiri Darban, S; Nikoofal-Sahlabadi, S; Amiri, N; Kiamanesh, N; Mehrabian, A; Zendehbad, B; Gholizadeh, Z; Jaafari, M Reza 2018: Targeting the leptin receptor: To evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor Colloids and Surfaces B: Biointerfaces 164: 107-115
Amiri Darban, S.; Nikoofal-Sahlabadi, S.; Amiri, N.; Kiamanesh, N.; Mehrabian, A.; Zendehbad, B.; Gholizadeh, Z.; Jaafari, M.R. 2018: Targeting the leptin receptor: to evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor Colloids and Surfaces. B Biointerfaces 164: 107-115
Lynch, D.H.; Rubin, A.S.; Miller, R.E.; Williams, D.E. 1992: Protective effects of rhuil 1 alpha in normal and tumor bearing mice treated with doxorubicin FASEB Journal 6(4): A1147
Hosokawa, M.; Sawamura, Y.; Morikage, T.; Okada, F.; Xu, Z.Y.; Morikawa, K.; Itoh, K.; Kobayashi, H. 1988: Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide Cancer Immunology Immunotherapy: Cii 26(3): 250-256